B
Bullisch
Bullisch · 25%KLRS
$2.74
Szenariopreis
$2.420
+0.061 (+2.54%)Zum Schluss
Loading chart…
- Hoch
- 2.660
- Eröffnung
- 2.360
- Volumengewichteter Durchschnittskurs
- 2.47
- Volumen
- 201.00K
- Marktkap.
- —
- Tief
- 2.340
- Umsatz
- 497.14K
- EV/EBITDA, TTM
- 0.00
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
KI-Analyse of Kalaris Therapeutics Inc (KLRS)
HaltenKalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Kalaris Therapeutics Inc (KLRS) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.86.
Alphio-AI-Kursszenarien für KLRS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die KLRS halten
Event-Zeitleiste
News
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
5.007-20seekingalphaKalaris Therapeutics Appoints New CFO
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in Retinal Diseases
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in AMD
- 2.007-17Newsfilter
Kalaris Reports Positive Data for TH103 in AMD Treatment
KLRS FAQ – beantwortet von Alphio AI
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO). It operates in the Healthcare sector.
Kalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.